• Novo Nordisk has received a formal warning letter from the US Food and Drug Administration regarding post marketing safety reporting.
• The FDA identified issues in how the company handled adverse event reports for certain products, including semaglutide.
• The warning highlights regulatory concerns around the company’s compliance with US drug safety reporting rules.

For investors following CPSE:NOVO B, this regulatory setback comes at a time when the share price stands at DKK247.0. The stock has seen a 21.6% decline over the past 30 days and a 25.2% decline year to date, with a 51.6% decline over the past year, which points to a challenging period for shareholders.

This FDA action adds another layer of risk to consider, particularly…